Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Mar 1;14(5):1455-63.
doi: 10.1158/1078-0432.CCR-07-0371.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

Dan Laheru  1 , Eric Lutz, James Burke, Barbara Biedrzycki, Sara Solt, Beth Onners, Irena Tartakovsky, John Nemunaitis, Dung Le, Elizabeth Sugar, Kristen Hege, Elizabeth Jaffee
Affiliations
Multicenter Study

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

Dan Laheru et al. Clin Cancer Res. .

Abstract

Purpose: The combination of chemotherapy and immunotherapy has not been examined in patients with advanced pancreatic cancer. We conducted a study of two granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines (CG8020/CG2505) as immunotherapy administered alone or in sequence with cyclophosphamide in patients with advanced pancreatic cancer.

Experimental design: This was an open-label study with two cohorts: cohort A, 30 patients administered a maximum of six doses of CG8020/CG2505 at 21-day intervals; and cohort B, 20 patients administered 250 mg/m(2) of cyclophosphamide i.v. 1 day before the same immunotherapy given as in cohort A. The primary objective was to evaluate safety and duration of immunity. Secondary objectives included time to disease progression and median overall survival.

Results: The administration of CG8020/CG2505 alone or in sequence with cyclophosphamide showed minimal treatment-related toxicity. Median survival values in cohort A and cohort B were 2.3 and 4.3 months, respectively. CD8(+) T-cell responses to HLA class I-restricted mesothelin epitopes were identified predominantly in patients treated with cyclophosphamide + CG8020/CG2505 immunotherapy.

Conclusion: Granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines CG8020/CG2505 alone or in sequence with cyclophosphamide showed minimal treatment-related toxicity in patients with advanced pancreatic cancer. Also, mesothelin-specific T-cell responses were detected/enhanced in some patients treated with CG8020/CG2505 immunotherapy. In addition, cyclophosphamide-modulated immunotherapy resulted in median survival in a gemcitabine-resistant population similar to chemotherapy alone. These findings support additional investigation of cyclophosphamide with CG8020/CG2505 immunotherapy in patients with advanced pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Figure 1
Figure 1. Comparison of the magnitude of CD8+ T cells specific for mesothelin versus the CEF pool of peptides
An Elispot analysis was performed to determine the number of interferon-gamma secreting T cells specific for mesothelin as described in Table 4. All patient lymphocytes were also assessed for recognition of an HIV negative control peptide and a positive antigen control pool of peptides (CEF pool). Background spots ranged from 0-10 spots/per well as described in Table 4. Graphed is the mesothelin specific T cell response data presented in Table 4 and the corresponding CEF pool specific CD8+ T cell responses. A. Immunotherapy Only Cohort. B. Cyclophosphamide + Immunotherapy Cohort. Striped bars=mesothelin data. Black bars=CEF pool data.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2006. CA Cancer J Clin. 2006;56:106–130. - PubMed
    1. Yeo CJ, Pluth-Yeo T, Hruban R, et al. Cancer of the Pancreas. In: DeVita VT, editor. Principles and Practice of Oncology. Seventh. Philadelphia: J.B. Lippincott Co; 2005. pp. 945–986.
    1. Burris HA, Moore MJ, Cripps MC, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol. 1997;15:2403–13. - PubMed
    1. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–52. - PubMed
    1. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–83. - PubMed

Publication types

MeSH terms

Substances